SCHEDULE: Avoro Capital Advisors Discloses Stake in Damora Therapeutics

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.27% of Damora Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Avoro Capital Advisors LLC, an investment advisor, and Behzad Aghazadeh, its portfolio manager, have jointly filed a Schedule 13G.
• They collectively beneficially own 3,783,000 shares of Damora Therapeutics, Inc. common stock.
• This ownership represents 6.27% of the company's outstanding common stock.
• The shares were acquired solely for investment purposes.
• The filing is based on Damora Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which reported 60,303,212 shares outstanding as of March 17, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard disclosure of beneficial ownership by an investment firm and does not inherently contain positive or negative news about the company's operations or financial performance.

Positives

• Significant stake acquired by a notable investment firm, potentially indicating confidence in the company's future.
• The filing confirms a substantial ownership percentage (6.27%) by Avoro Capital Advisors and Behzad Aghazadeh.

Risks

• The filing does not detail specific risks associated with Damora Therapeutics, Inc. beyond the general nature of stock ownership.
• Potential for future stock sales by Avoro Capital Advisors could impact share price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Damora Therapeutics, Inc. It is a disclosure of beneficial ownership.

Management Comments

• The filing should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
• Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Avoro Capital Advisors' strategic interest in Damora Therapeutics, potentially signaling a belief in the company's growth prospects within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Damora Therapeutics, potentially influencing investor sentiment and share price.
• Management: The significant stake held by Avoro Capital Advisors may lead to increased engagement or scrutiny from the reporting persons.
• Potential Investors: This filing provides transparency regarding a major shareholder, which can be a factor in investment decisions.

Next Steps

• Avoro Capital Advisors LLC and Behzad Aghazadeh will continue to monitor their investment in Damora Therapeutics, Inc.
• Future amendments to the Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide operational or financial performance data for Damora Therapeutics. Therefore, a 'hold' recommendation is appropriate as it suggests maintaining the current investment position pending further information about the company's business and financial health.

Keywords

Damora Therapeutics, Schedule 13G, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, Investment, Common Stock, SEC Filing